Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T12:45:46.924Z.
Calculation as of: 2026-10-06T12:45:46.924Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$1.52B
EBITDA Yield
1.37%
TTM Avg
0.46%
3Y Avg
1.07%
5Y Avg
1.02%
Market Cap
$1.45B
EBITDA Yield
11.15%
TTM Avg
6.15%
3Y Avg
7.10%
5Y Avg
6.61%
Market Cap
$1.43B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.65B
EBITDA Yield
1.74%
TTM Avg
1.16%
3Y Avg
1.16%
5Y Avg
1.16%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | $1.51B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.52B | N/A | N/A | N/A | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.52B | 1.37% | 0.46% | 1.07% | 1.02% |
| AnaptysBio, Inc. (ANAB)vs › | $1.46B | 8.52% | 3.11% | 3.11% | 3.25% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 11.15% | 6.15% | 7.10% | 6.61% |
| Certara, Inc. (CERT)vs › | $1.57B | 3.53% | 6.63% | 3.69% | 3.19% |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | N/A | N/A | N/A | N/A |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.65B | 1.74% | 1.16% | 1.16% | 1.16% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.65B | 14.56% | 10.69% | 8.08% | 6.99% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
